A Phase I Study of G3139 Subcutaneous in Solid Tumors

Inclusion Criteria: * A Confirmed diagnosis of a solid tumor malignancy, not to include lymphoma, that has failed standard therapy or for which no standard therapy is available. Patients with a history of brain metastasis will be eligible if there is no evidence of cerebral edema or treatment with steroids. * Adequate organ function as determined \< 7 days prior to starting study medication * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * At least 3 weeks and recovery from effects of major prior surgery or other therapy including radiation therapy, immunotherapy, cytokine, biological, vaccine and chemotherapy Exclusion Criteria: * Significant medical diesese * History of leptomeningeal disease * Coexisting condition that would require the subject to continue therapy during the treatment phase of the study with a drug known to alter renal function. * Use of any investigational drug within 3 weeks prior to starting study medication * Known hypersensitivity to phosphorothioate-containing oligonucleotides * Pregnancy/Lactation